AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan

Published On 2022-12-31 12:15 GMT | Update On 2022-12-31 12:15 GMT

New Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trial of the anticancer drug Datopotamab deruxtecan.

This came after the drug major AstraZeneca presented Phase III clinical trial protocol no D926NC, version 1.0 dated 15-07-2022, local clinical trial protocol addendum IND-1, version 1.0 dated 11-08-2022 before the committee.

Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer.

Datopotamab deruxtecan is an antibody-drug conjugate with three components: a humanized anti–Trop-2 IgG1 monoclonal antibody attached to a topoisomerase 1 inhibitor payload via a tetrapeptide-based cleavable linker. It was designed with these key attributes: topoisomerase 1 inhibition as the payload mechanism of action; a payload with high potency, short systemic half-life, and stable linker; optimized drug-to-antibody ratio; tumour-selective cleavable linker; and bystander antitumor effect,

At the recent SEC meeting for oncology and hematology held on December 9th 2022, the expert panel reviewed the Phase III clinical trial protocol of the anticancer drug Datopotamab Deruxtecan (Dato-DXD).

After detailed deliberation, the committee recommended the grant of permission to conduct the study of the anticancer drug Datopotamab deruxtecan.

Also Read: DCGI calls out WHO for 'prematurely' blaming Maiden Pharma for cough syrup linked deaths in Gambia

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan

Similar News

Gufic Biosciences appoints Rajesh Kaul as Senior President - Sparsh Cluster

Alembic buys UTI-focused Utility Therapeutics in USD 12 million deal

Biocon Biologics gets EU nod for bone disease treatments, including Osteoporosis, giant cell tumour of bone

Aurobindo Pharma arm gets marketing nod for Dazublys from European Commission

Lincoln Pharma to begin API production at Khatraj facility in 1- 2 years

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC

Delhi HC Rejects Modi-Mundipharma's Monopoly Claim Over 'CONTIN', Allows Limited Relief

Natco Pharma sees major leadership exit in RnD, demand & supply, quality